Association between interleukin gene polymorphisms and susceptibility to gastric cancer in the Qinghai population

Xiaoyan Song1*, Dongmei Wang2*, Baji Ben1, Chenghua Xiao1, Liyan Bai1, Han Xiao3, Wenyan Zhang1, Wanchao Li4, Jingying Jia4 and Yujuan Qi1

Abstract

Objective: To investigate the associations between interleukin (IL) gene polymorphisms and susceptibility to gastric cancer in the Qinghai population, China.

Methods: Patients with gastric cancer and cancer-free controls were enrolled into the study from Qinghai Provincial People’s Hospital between September 2016 and September 2018. Single nucleotide polymorphisms (SNPs) were genotyped with the Sequenom MassARRAY® SNP genotyping system. The Hardy–Weinberg equilibrium in allele and genotype frequencies, and general characteristics between patients with gastric cancer and cancer-free controls, were evaluated using $\chi^2$-test. Potential associations between interleukin gene variants and the risk of gastric cancer were analysed by logistic regression.

Results: Among eight candidate SNPs, the allele and genotype frequency distribution of IL-1B rs1143634 polymorphism was significantly different between patients with gastric cancer ($n=190$) and cancer-free controls ($n=186$). The IL-1B rs1143634 GA genotype and IL-1B rs1143634 GA+AA genotype were associated with a reduced risk of gastric cancer, however, the remaining SNPs were not statistically associated with gastric cancer risk in the Qinghai population.

1Department of Medical Oncology, Qinghai Provincial People’s Hospital, Xining, China
2Department of Oncology, Affiliated Hospital of Heze Medical College, Heze, China
3Department of Medical Oncology, Qinghai University Affiliated Hospital, Xining, China
4Graduate School, Qinghai University, Xining, China

*These authors contributed equally to this work.

Corresponding author:
Yujuan Qi, Department of Medical Oncology, Qinghai Provincial People’s Hospital, 2 Gonghe Road, Chengdong District, Xining, Qinghai, 810007, China.
Email: qiyujuanxn@outlook.com
Conclusion: The IL-1B rs1143634 polymorphism might be associated with a decreased risk of gastric cancer, and may be a protective factor against gastric cancer.

Keywords
Gastric cancer, susceptibility, interleukin (IL) genes, polymorphisms, IL-1B rs1143634, cancer risk

Date received: 31 January 2021; accepted: 3 March 2021

Introduction
In 2018, approximately 18.1 million new cancer cases and 9.6 million cancer deaths were reported worldwide. Gastric cancer is considered to be the fourth most common malignancy and the second highest cause of cancer death globally, with varying incidence rates between different regions. More than half of gastric cancer cases are reported in developing countries, and particularly in East Asia, including China. The development of gastric cancer is a complex multistep and multifactorial process, caused by a combination of environmental factors, such as Helicobacter pylori, Epstein-Barr Virus (EBV) infection, dietary habits, and genetic factors, including genetic alterations and epigenetic modifications. Research is increasingly illustrating the importance of microorganisms in the development of gastric cancer. Moreover, genetic factors, shown to be closely associated with gastric cancer, are also attracting growing attention. Thus, exploring potential underlying genetic factors in gastric cancer may help in the development of effective treatments, and is of great clinical concern.

Chronic inflammation is a significant feature of gastric cancer. As important mediators of the immune system, cytokines play a crucial role in cell proliferation, tissue development, gene expression, DNA repair and inflammation, and they are considered to be the significant link between inflammation and cancer. The chronic inflammation associated with gastric cancer development involves proinflammatory factors, such as interleukin (IL)-1B, IL-8, and tumour necrosis factor (TNF)-α, and also anti-inflammatory factors, such as IL-10. Several studies have reported that IL gene polymorphisms are associated with gastric carcinogenesis, and may influence the susceptibility to gastric cancer. For example, a significant positive association between IL-1B +3954 genotype distribution and gastric cancer was observed in the Iranian population, and the IL-1B gene polymorphism was found to be an important risk factor for gastric cancer. Results of a case–control study suggested that the IL-10 C819T polymorphism was associated with an increased risk of gastric cancer in co-dominant, dominant, and recessive models. Less direct associations have also been suggested. For example, Ying et al. indicated that the effects of the IL-1B 31 polymorphism on gastric cancer susceptibility rely largely on the presence of H. pylori. Therefore, it is imperative to further investigate the relationship between IL polymorphisms and gastric cancer, to illustrate their specific role in gastric cancer.

Qinghai, China is located on the Qinghai-Tibet plateau, and is situated in a multi-ethnic region that mainly includes Han, Tibetan, Hui, and Mongolian ethnicities. The incidence of gastric cancer in the Qinghai area is relatively high, possibly due to factors such as race, geographical location, and the environment. The aim of the present case–control study was to investigate a potential correlation between IL polymorphisms and susceptibility to gastric cancer in the Qinghai population, by analysing the
association between gastric cancer and IL-1B rs1143627, IL-1B rs1143634, IL-8 rs4073, IL-10 rs1800896, IL-16 rs4778889, IL-18 rs917997, IL-22 rs1179251, and IL-32 rs2015620 in a Qinghai study population of patients with gastric cancer and cancer-free controls.

Patients and methods

Study population

This observational, cross-sectional case–control study included patients with gastric cancer and cancer-free controls, aged between 18 and 70 years, recruited from Qinghai Provincial People’s Hospital, Qinghai Province, China, between September 2016 and September 2018. All study participants were long-term residents of Qinghai Province, China. Inclusion criteria were: availability of tissue samples obtained from surgical or endoscopic examination, and new diagnosis of gastric cancer based on postoperative pathology data. Non-Qinghai residents or patients with benign gastric lesions and other malignant tumours were excluded. Sex- and age-matched (±3 years) cancer-free controls were selected from health screening program participants with complete clinical information and without personal or immediate family history of gastric cancer. Demographic and clinical data were collected, including age, sex, nationality, smoking status, drinking status, presence of H. pylori infection, and family history of cancer. The study was approved by the Ethics Committee of Qinghai Provincial People’s Hospital, and written informed consent was obtained from all participants.

DNA extraction, PCR amplification and genotyping

Peripheral venous blood (5 ml) was collected from each participant into ethylenediaminetetra-acetic acid anticoagulant tubes and stored at –80°C prior to use. Genomic DNA was extracted using TIANamp Blood DNA Kits (Tiangen, Beijing, China). The IL single nucleotide polymorphism (SNP) genotypes were then determined using a Sequenom MassARRAY® SNP genotype system (Sequenom, San Diego, CA, USA). The specific IL SNP primer sequences (Sangon, Shanghai, China), amplicon lengths and genotypes are described in Table 1. Genomic DNA samples were quantitatively diluted and placed into wells of a 384-well plate with the designed sequence shown in Table 1. Target sequences were then amplified by polymerase chain reaction (PCR) in a total reaction volume of 5 μl containing 20–50 ng DNA, 10 × PCR buffer (iPLEX GOLD Reagent Kit, Agena Bioscience, Beijing, China), 0.4 μl MgCl₂ (25 mM), 0.1 μl dNTPs (25 mM), 0.1 μl HotStar Taq DNA polymerase (5 U/μl; Agena Bioscience), 1.9 μl H₂O, and 1 μl PCR primer mix. The PCR conditions were as follows: an initial extension at 94°C for 4 min, followed by 45 cycles of 94°C for 20 s, 56°C for 30 s, and 72°C for 60 s, final extension at 72°C for 3 min, then held at 4°C. The PCR products were treated with alkaline phosphatase to remove any remaining dNTPs, after which, a single-base extension reaction was performed under the following conditions: 94°C for 30 s, 94°C for 5 s, 52°C for 5 s, and 80°C for 5 s. Following resin purification, the reaction products were moved into SpectroCHIP chips (Sequenom), and genotypes were detected using matrix-assisted laser desorption ionization-time of flight mass spectrometry (Sequenom MassARRAY®).

Statistical analyses

Data are presented as n (%) prevalence or mean ± SD. Statistical analyses were performed using SPSS software, version 17.0 (SPSS Inc., Chicago, IL, USA). χ²-test
| SNP     | 2nd-PCRP  | 1st-PCRP  | AMP  | UEP_SEQ          | Genotype |
|---------|-----------|-----------|------|------------------|----------|
| rs1143627 | AGTTGGATGCTCAGAGGTTGTTGCCACCTG | 98 | TTCTCCCTGCTGTATTAT | AG, AA, GG |
| rs1143634 | AGTTGGATGCTCAGAGGTTGTTGCCACCTG | 100 | ACATTTCAGAACCCTATCTTCTT | GA, GG, AA |
| rs4073   | AGTTGGATGCTCAGAGGTTGTTGCCACCTG | 118 | CCAATTGTTGGAATTATCAA | TA, TT, AA |
| rs1800896 | AGTTGGATGCTCAGAGGTTGTTGCCACCTG | 107 | tCCTATCCCTACTTCCC | CT, CC, TT |
| rs477889 | AGTTGGATGCTCAGAGGTTGTTGCCACCTG | 99 | gCAAAGGCTTTTTGGTCTATCA | CT, CC, TT |
| rs917997 | AGTTGGATGCTCAGAGGTTGTTGCCACCTG | 113 | ATGCTAGAACCAGCTAT | CT, CC, TT |
| rs1179251 | AGTTGGATGCTCAGAGGTTGTTGCCACCTG | 101 | ACTGACCACCCAAGCTAT | CG, CC, GG |
| rs2015620 | AGTTGGATGCTCAGAGGTTGTTGCCACCTG | 102 | GTGCTCACTCAATCTTC | TA, TT, AA |

SNP, single nucleotide polymorphism.

a2nd-PCRP, secondary (reverse) amplification primer (including secondary tag);
b1st-PCRP, primary (forward) amplification primer (including primer tag);
cAMP, amplicon length (in bases; including primer tags and maximum SNP sequence length);
dUEP_SEQ, extend primer sequence (used in the single-base extension reaction for genotype identification).
was used to evaluate the Hardy–Weinberg equilibrium (HWE) in allele and genotype frequencies, and categorical data regarding general characteristics between patients with gastric cancer and cancer-free controls. The odds ratios (ORs) and 95% confidence intervals (CIs) from unconditional logistic regression were used to assess the potential associations between genetic variants of interleukin genes and gastric cancer risk. ORs were adjusted according to age, sex, nationality, *H. pylori* infection, tobacco smoking, alcohol drinking and family history of cancer. A *P*-value < 0.05 was defined as statistically significant.

**Results**

**Demographic and clinical characteristics in patients with gastric cancer versus healthy controls**

A total of 190 patients with gastric cancer and 186 cancer-free controls from the Qinghai population were included. Statistically significant differences were found in age, sex, *H. pylori* infection status and nationality between patients with gastric cancer and cancer-free controls (*P < 0.05*; Table 2), while no significant between-group differences were found in

| Table 2. Demographic and clinical characteristics of patients with gastric cancer and cancer-free controls from the Qinghai region. |
|---------------------------------------------------------------|
| **Characteristic** | **Cases** | **n (%)** | **Controls** | **n (%)** | **χ^2-value** | **Statistical significance** |
| Number | 190 (50.53) | 186 (49.47) |
| Age | | | 8.987 | *P < 0.001* |
| Year | 56.76 ± 11.584 | 48.26 ± 9.17 |
| < 60 years | 108 (56.84) | 179 (96.24) | 5.917 | < 0.05 |
| ≥ 60 years | 82 (43.16) | 7 (3.76) |
| Sex | | | 21.476 | *P < 0.001* |
| Male | 148 (77.89) | 103 (55.38) | 21.476 | *P < 0.001* |
| Female | 42 (22.11) | 83 (44.62) |
| Nationality | | | 10.413 | *P = 0.001* |
| Han population | 124 (65.26) | 149 (80.11) | 10.413 | *P = 0.001* |
| Minority nationalities | 66 (34.74) | 37 (19.89) |
| Tobacco smoking | | | 0.251 | NS |
| Yes | 68 (35.79) | 62 (33.33) | 0.251 | NS |
| No | 122 (64.21) | 124 (66.67) |
| Alcohol drinking | | | 0.638 | NS |
| Yes | 68 (35.79) | 74 (39.78) | 0.638 | NS |
| No | 122 (64.21) | 112 (60.22) |
| *Helicobacter pylori* infection | | | 25.094 | *P < 0.001* |
| Positive | 152 (80.00) | 104 (55.91) | 25.094 | *P < 0.001* |
| Negative | 38 (20.00) | 82 (44.09) |
| Family history of cancer | | | 2.465 | NS |
| Yes | 17 (8.95) | 9 (4.84) | 2.465 | NS |
| No | 173 (91.05) | 177 (95.16) |

Data presented as n (%) prevalence or mean ± SD.

NS, no statistically significant between-group difference (*P > 0.05*; χ^2-test).
tobacco smoking, alcohol drinking, and family history of cancer ($P > 0.05$; Table 2).

**Allele and genotype frequency distribution**

The genotype and allele frequencies of eight SNPs (IL-1B rs1143627, IL-1B rs1143634, IL-8 rs4073, IL-10 rs1800896, IL-16 rs4778889, IL-18 rs917997, IL-22 rs1179251 and IL-32 rs2015620) in patients with gastric cancer and cancer-free controls are summarized in Table 3. The genotype frequencies fitted the HWE in gastric cancer cases and cancer-free controls except for IL-1B rs1143634. The IL-1B rs1143634 SNP showed statistically significant differences in allele frequency distributions between gastric cancer cases (G, 93.42%; A, 6.58%) and cancer-free controls (G, 97.85%; A, 2.15%; $\chi^2 = 8.786$, $P = 0.003$), and differences in genotype frequency distributions between gastric cancer cases (GA, 10.00%; GG, 88.42%; AA, 1.58%) and cancer-free controls (GA, 4.30%; GG, 95.70%; AA, 0.00%; $\chi^2 = 7.311$, $P = 0.016$). No statistically significant between-group differences in genotype or allele frequencies were observed for the other SNPs (all $P > 0.05$; Table 3).

**Association between interleukin gene polymorphisms and gastric cancer risk**

Logistic regression analyses of the potential associations between IL gene polymorphisms and risk of gastric cancer are shown in Table 4. The IL-1B rs1143634 GA genotype (OR 0.242, 95% CI 0.088, 0.670; $P = 0.006$) and IL-1B rs1143634 GA + AA genotype (OR 0.227, 95% CI 0.084, 0.618; $P = 0.004$) were found to be associated with a reduced risk of gastric cancer. The other investigated SNPs were not found to be statistically associated with gastric cancer risk in the Qinghai population ($P > 0.05$).

**Discussion**

Gastric cancer remains one of the most common cancers, accounting for approximately 424,000 new cases annually in China, and its incidences in men and women are the fifth and third highest, respectively, among all malignant tumours in China. Inflammatory factors are increasingly recognized as being associated with the pathogenesis of gastric cancer, with numerous studies reporting a relationship between chronic inflammation and gastric cancer occurrence and development. Environmental and genetic factors are also involved in gastric cancer development. In the present study, the association between eight IL SNPs and the risk of gastric cancer was investigated, and a significant difference was observed in the allele and genotype frequency distribution of the IL-1B rs1143634 gene polymorphism between patients with gastric cancer and cancer-free controls. In addition, the IL-1B rs1143634 GA and AA + GA genotypes were found to be statistically associated with a reduced susceptibility to gastric cancer compared with GG genotype carriers. To the best of our knowledge, this is the first report on the vital roles of IL gene polymorphisms in gastric cancer among the Qinghai population, China.

Interleukin-1β, encoded by *IL-1B*, is a member of the interleukin 1 family of cytokines, and is both a pro-inflammatory factor produced by activated macrophages and other cell types, and an effective inhibitor of gastric acid secretion. The *IL-1B* gene is located on chromosome 2q13 in humans. The *IL-1B* +3954 C/T polymorphisms in the promoter region and +3954 (rs1143634) polymorphisms in exon 5 are two functional SNPs of the *IL-B* gene. Two previous studies reported an association between the IL-1B +3954 C/T polymorphism and risk of gastric cancer. However, another study showed no significant
Table 3. Genotype and allele frequencies of interleukin gene polymorphisms in patients with gastric cancer and healthy controls from the Qinghai region.

| SNP genotype | Study group |
|--------------|-------------|
|              | Cases       | Controls    | \(\chi^2\)-value | Statistical significance |
| IL-1B rs1143627 |             |             |                 |                         |
| AG           | 95 (50.00)  | 99 (53.22)  | 0.627           | NS                       |
| AA           | 46 (24.21)  | 39 (20.97)  |                 |                          |
| GG           | 49 (25.79)  | 48 (25.81)  |                 |                          |
| A allele     | 187 (49.21) | 177 (47.58) | 0.2             | NS                       |
| G allele     | 193 (50.79) | 195 (52.42) |                 |                          |
| IL-1B rs1143634 |           |             |                 |                         |
| GA           | 19 (10.00)  | 8 (4.30)    | 7.311           | P = 0.016*               |
| GG           | 168 (88.42) | 178 (95.70) |                 |                          |
| AA           | 3 (1.58)    | 0 (0.00)    |                 |                          |
| G allele     | 355 (93.42) | 364 (97.85) | 8.786           | P = 0.003                |
| A allele     | 25 (6.58)   | 8 (2.15)    |                 |                          |
| IL-8 rs4073  |             |             |                 |                         |
| TA           | 88 (46.32)  | 89 (47.85)  | 0.143           | NS                       |
| TT           | 72 (37.89)  | 67 (36.02)  |                 |                          |
| AA           | 30 (15.79)  | 30 (16.13)  |                 |                          |
| T allele     | 232 (61.05) | 223 (59.95) | 0.096           | NS                       |
| A allele     | 148 (38.95) | 149 (40.05) |                 |                          |
| IL-10 rs1800896 |         |             |                 |                         |
| CT           | 30 (15.79)  | 31 (16.67)  | 0.445           | NS*                      |
| CC           | 2 (1.05)    | 1 (0.54)    |                 |                          |
| TT           | 158 (83.16) | 154 (82.80) |                 |                          |
| C allele     | 34 (8.95)   | 33 (8.87)   | 0.001           | NS                       |
| T allele     | 346 (91.05) | 339 (91.13) |                 |                          |
| IL-16 rs4778889 |       |             |                 |                         |
| CT           | 75 (39.47)  | 83 (44.62)  | 1.055           | NS                       |
| CC           | 12 (6.32)   | 10 (5.38)   |                 |                          |
| TT           | 103 (54.21) | 93 (50.00)  |                 |                          |
| C allele     | 99 (26.05)  | 103 (27.69) | 0.256           | NS                       |
| T allele     | 281 (73.95) | 269 (72.31) |                 |                          |
| IL-18 rs917997 |       |             |                 |                         |
| CT           | 83 (43.68)  | 92 (49.46)  | 1.294           | NS                       |
| CC           | 56 (29.47)  | 48 (25.81)  |                 |                          |
| TT           | 51 (26.84)  | 46 (24.73)  |                 |                          |
| C allele     | 195 (51.32) | 188 (50.54) | 0.046           | NS                       |
| T allele     | 185 (48.68) | 184 (49.46) |                 |                          |
| IL-22 rs1179251 |      |             |                 |                         |
| CG           | 73 (38.42)  | 89 (47.85)  | 4.878           | NS                       |
| CC           | 94 (49.47)  | 84 (45.16)  |                 |                          |
| GG           | 23 (12.11)  | 13 (6.99)   |                 |                          |
| C allele     | 261 (68.68) | 257 (69.09) | 0.014           | NS                       |
| G allele     | 119 (31.32) | 115 (30.91) |                 |                          |
association between IL-1B rs1143627 and rs1143634 polymorphisms and gastric cancer, and a meta-analysis revealed that IL-1B \(31\ C > T\) polymorphism was not significantly associated with gastric cancer risk. In the present case–controlled study, subjects carrying the IL-1B rs1143634 GA or AA + GA genotype had a reduced risk of gastric cancer, suggesting that these genotypes may be protective against gastric cancer. However, the genotype frequencies of IL-1B rs1143634 did not conform to the HWE law, probably due to the small sample size. Therefore, the sample size should be expanded in a subsequent study to further confirm these results. No statistically significant difference was found between patients with gastric cancer and cancer-free controls in terms of the IL-1B rs1143627 polymorphisms.

Interleukin-8 is a chemokine secreted by a variety of cells, such as neutrophils, monocytes, endothelial cells and epithelial cells. As a neutrophil activator, IL-8 can promote the angiogenic response of endothelial cells, recruitment of neutrophils to a tumour site, and the proliferation, survival, and migration of tumour cells in tumour progression. The \(IL-8\) gene is located on chromosome 4q12-q13, comprising four exons and three introns, and the common polymorphism is IL8-251T/A (rs4073) at the promoter region. Chang et al. found that a combination of \(H. pylori\) infection and the IL-8 -251 T > A polymorphism might increase the risk of severe atrophic gastritis and gastric cancer in a Korean population, and results of a meta-analysis indicated that the IL-8 -251 AA genotype was associated with the overall risk of developing gastric cancer and may increase the overall gastric cancer susceptibility in Asian populations. No significant relationship was revealed between IL8 rs4073 and gastric cancer in the present Qinghai population, which concurred with a previous report that the IL-8 rs4073 polymorphism was not significantly related to risk of gastric cancer in a high-risk Chinese population.

Interleukin-10, a multifunctional cytokine produced by immune cells in viral infections, can modulate the function of immune cells and protect the host from tissue damage during the acute phase of the immune response. Furthermore, it is vital for the maintenance of normal physiology and suppression of cancer development, and keeps a balance between proinflammatory and anti-inflammatory processes.

Table 3. Continued.

| SNP genotype | Cases \(n = 190\) | Controls \(n = 186\) | \(\chi^2\)-value | Statistical significance |
|--------------|----------------|----------------|----------------|------------------------|
| IL-32 rs2015620 |               |               |               |                       |
| TA           | 84 (44.21)    | 94 (50.54)    | 1.579         | NS                     |
| TT           | 55 (28.95)    | 46 (24.73)    |               |                        |
| AA           | 51 (26.84)    | 46 (24.73)    |               |                        |
| T allele     | 194 (51.05)   | 186 (50.00)   | 0.083         | NS                     |
| A allele     | 186 (48.95)   | 186 (50.00)   |               |                        |

Data presented as \(n (\%\) prevalence.
SNP, single nucleotide polymorphism.
*Analysed using Fisher’s exact test.
NS, no statistically significant between-group difference (\(P > 0.05; \chi^2\)-test).
**Table 4.** Association between gastric cancer risk and interleukin gene polymorphisms in the Qinghai population.

| SNP genotype | Cases n = 190 | Controls n = 186 | OR (95% CIs) | Statistical significance |
|--------------|--------------|-----------------|--------------|-------------------------|
| **IL-1B rs1143627** | | | | |
| AA           | 46 (24.21)   | 39 (20.97)      | 1.00         |                         |
| AG           | 95 (50.00)   | 99 (53.22)      | 1.700 (0.912, 3.168) | NS                      |
| GG           | 49 (25.79)   | 48 (25.81)      | 1.746 (0.861, 3.544) | NS                      |
| AG+GG        | 144 (75.79)  | 147 (79.03)     | 1.715 (0.949, 3.099) | NS                      |
| **IL-1B rs1143634** | | | | |
| GG           | 168 (88.42)  | 178 (95.70)     | 1.00         |                         |
| GA           | 19 (10.00)   | 8 (4.30)        | 0.242 (0.088, 0.670) | \(P = 0.006\)          |
| AA           | 3 (1.58)     | 0 (0.00)        | 0.000 (0.000) | NS                      |
| GA+AA        | 22 (11.58)   | 8 (4.30)        | 0.227 (0.084, 0.618) | \(P = 0.004\)         |
| **IL-8 rs4073** | | | | |
| TT           | 72 (37.89)   | 67 (36.02)      | 1.00         |                         |
| TA           | 88 (46.32)   | 89 (47.85)      | 0.684 (0.327, 1.433) | NS                      |
| AA           | 30 (15.79)   | 30 (16.13)      | 0.968 (0.475, 1.974) | NS                      |
| TA+AA        | 118 (62.11)  | 119 (63.98)     | 1.427 (0.860, 2.368) | NS                      |
| **IL-10 rs1800896** | | | | |
| CC           | 2 (1.05)     | 1 (0.54)        | 1.00         |                         |
| CT           | 30 (15.79)   | 31 (16.67)      | 4.238 (0.243, 73.902) | NS                      |
| TT           | 158 (83.16)  | 154 (82.80)     | 3.17 (0.192, 52.317) | NS                      |
| CT+TT        | 188 (98.95)  | 185 (99.46)     | 3.309 (0.200, 54.640) | NS                      |
| **IL-16 rs4778889** | | | | |
| CC           | 12 (6.32)    | 10 (5.38)       | 1.00         |                         |
| CT           | 75 (39.47)   | 83 (44.62)      | 1.088 (0.388, 3.048) | NS                      |
| TT           | 103 (54.21)  | 93 (50.00)      | 0.941 (0.340, 2.603) | NS                      |
| CT+TT        | 178 (93.68)  | 176 (94.62)     | 1.004 (0.372, 2.708) | NS                      |
| **IL-18 rs917997** | | | | |
| CC           | 56 (29.47)   | 48 (25.81)      | 1.00         |                         |
| CT           | 83 (43.68)   | 92 (49.46)      | 1.343 (0.739, 2.440) | NS                      |
| TT           | 51 (26.84)   | 46 (24.73)      | 0.744 (0.381, 1.454) | NS                      |
| CT+TT        | 134 (70.53)  | 138 (74.19)     | 1.080 (0.622, 1.873) | NS                      |
| **IL-22 rs1179251** | | | | |
| CC           | 94 (49.47)   | 84 (45.16)      | 1.00         |                         |
| CG           | 73 (38.42)   | 89 (47.85)      | 1.687 (0.997, 2.853) | NS                      |
| GG           | 23 (12.11)   | 13 (6.99)       | 0.565 (0.234, 1.366) | NS                      |
| CG+GG        | 96 (50.53)   | 102 (54.84)     | 1.378 (0.841, 2.257) | NS                      |
| **IL-32 rs2015620** | | | | |
| TT           | 55 (28.95)   | 46 (24.73)      | 1.00         |                         |
| TA           | 84 (44.21)   | 94 (50.54)      | 1.363 (0.754, 2.464) | NS                      |
| AA           | 51 (26.84)   | 46 (24.73)      | 1.409 (0.723, 2.748) | NS                      |
| TA+AA        | 135 (71.05)  | 140 (75.27)     | 1.379 (0.793, 2.397) | NS                      |

Data presented as n (%) prevalence.
SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
NS, no statistically significant correlation (\(P > 0.05\)).
signals provided by different T-cell populations. The IL-10 gene is located on chromosome 1 at 1q31-32, and IL-10-1082 (G/A), -819 (C/T), -592 (C/A) are three of the most studied SNPs. In a meta-analysis, IL-10 gene polymorphisms were suggested to be associated with cancer risk in the Chinese population. Results from a clinical study revealed that the IL-10-1082 gene was a susceptibility gene for gastric cancer, and the IL-10-1082 A/G (rs1800896) polymorphism has been suggested to contribute to gastric cancer susceptibility, particularly among Asians. In the present study population, no significant association was found between the IL-10 rs1800896 polymorphism and gastric cancer risk, which concurs with previous research.

Interleukin-16 is a multifunctional proinflammatory cytokine and lymphocyte chemoattractant that not only regulates the inflammatory process, but also regulates tumorigenesis. The IL-16 gene is located on chromosome 15q26.3 of the human genome, and the rs4778889 polymorphism is located at position -295 in the promoter region of this gene, which is related to gene expression. One study reported that the IL-16 rs4778889 CC genotype was related with elevated risk of non-cardia gastric cancer in the Chinese population. However, the results of a meta-analysis suggested there was no statistically significant association between the IL-16 rs4778889 T/C polymorphism and risk of cancer in the Asian population. The present study also failed to reveal any significant association between IL-16 rs4778889 and risk of gastric cancer, suggesting that the IL-16 rs4778889 polymorphism may not affect gastric cancer susceptibility.

Interleukin-18, as a member of the IL-1 family of cytokines, is a pleiotropic immune regulator that plays a powerful pro-inflammatory role by inducing interferon-γ. As the immune-stimulating effect of IL-18 has antitumour properties, IL-18 has been recommended as a new adjuvant therapy for cancer. The IL-18 receptor (IL-18R) is composed of an IL-18R accessory protein (IL-18RAP) and IL-18R1 protein, and the IL-18RAP rs917997 is located at 1.5 kb downstream of IL-18RAP. The IL-18RAP rs917997 C allele may be a protective factor against Barrett’s oesophagus and oesophageal adenocarcinoma, however, the result of another study showed no association between the IL-18RAP rs917997 C>T polymorphisms and the risk of oesophageal squamous cell carcinoma. Wang et al. found that the IL-18RAP rs917997 G allele might be protective against gastric cancer in a high-risk Chinese population. In the present study, the allele and genotype frequency distributions of the IL-18RAP rs917997 polymorphism were not significantly different between patients with gastric cancer and cancer-free controls, and there was no relationship between the IL-18RAP rs917997 polymorphism and gastric cancer risk. This may have been due to differences in race, region, and genotype in the study population, and also the relatively small size of the sample.

Interleukin-22 is a member of the IL-10 family of cytokines that includes IL-10, IL-19, IL-20, IL-24, IL-26, IL-28 and IL-29. IL-22 plays a crucial role in inflammation and tumorigenesis, and the IL-22 rs1179251 polymorphism is associated with increased risk of cancer. In addition, IL-22 rs1179251 was shown to be related to advanced stages, lymph node metastases, and distant metastases of gastric cancer, suggesting it may influence gastric cancer progression.

The human IL-32 gene resides on chromosome 16 p13.3 and comprises eight small exons. Although IL-32 was originally reported to be a pro-inflammatory cytokine in 2005, some studies revealed IL-32 to be involved in cancer cell growth and...
metastasis, by regulating nuclear factor (NF)-κB, which is a transcription factor and modulates growth factors and apoptosis inhibitors. IL-32 has also been implicated in cancer cell growth through its interaction with signal transducer and activator of transcription 3 (STAT3) signalling, which has been shown to promote cancer development. Furthermore, IL-32 was reported to promote colon cancer cell death via regulation of the p38/mitogen-activated protein kinase (MAPK) signalling pathway. The above research indicates that IL-32 is involved in multiple cancers by regulating NF-κB, STAT3 and MAPK signalling pathways. IL-32 is also reported to be involved in the occurrence and progression of gastric cancer. For example, Tsai et al. suggested that IL-32 was associated with increasing human gastric cancer cell invasion, contributing to gastric cancer progression and metastasis. Wang et al. observed that the IL-32 rs2015620 A allele was associated with increasing risk of gastric cancer, suggesting that the IL-32 rs2015620 polymorphism may be involved in gastric cancer development, and in particular, advanced gastric lesions. These studies reported the possible associations of IL-22 rs1179251 and IL-32 rs2015620 with the susceptibility to gastric cancer, and their possible participation in gastric cancer progression. However, the present study found no statistically significant associations between the IL-22 or IL-32 polymorphisms and susceptibility to gastric cancer.

The above research results indicate the importance of IL in the occurrence and development of gastric cancer. In addition to these critical ILs, others, including IL-6, IL-17, IL-23, have also been shown to play an important role in gastric cancer. For example, translational levels of IL-17 and IL-23 have been shown to differ in the pathogenesis of different types of gastric neoplasms, and IL ratios may be promising in the diagnosis of gastric cancer in humans. Although the results of the present study may be limited by the single-centre setting and the relatively small Qinghai study population, many previously published reports have shown that abnormal IL expression in humans is related to gastric cancer. The results of the present study should be verified by future research involving larger sample sizes and different populations.

Conclusions

In conclusion, the present study results suggest that the IL-1B rs1143634 polymorphism may be an important factor in reducing the risk of gastric cancer in the Qinghai population, China. IL-8, IL-10, IL-16, IL-18RAP, IL-22 and IL-32 genetic polymorphisms may influence the susceptibility to gastric cancer, but no statistically significant association with gastric cancer was observed, possibly due to differences in race, geographical region, sample size and genotype methods between the present study and previous research.

Author contributions

Xiaoyan Song made substantial contributions to the study conception and design, and to data acquisition, analysis and interpretation; Dongmei Wang performed the experiments; Baji Ben, Chenghua Xiao and Liyan Bai were involved in drafting the manuscript or revising it critically for important intellectual content; Han Xiao, Wenyan Zhang, Wanchao Li and Jingying Jia gave final approval of the version to be published. Yujuan Qi agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.
Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Leading project of Qinghai provincial health committee (NO: 20180104), Qinghai provincial people’s hospital project (NO: 2018016), The “Kunlun Talents” of Qinghai–Top-Notch and Pioneering talent of Innovation and Entrepreneurship (Qingrencai2020-10), and General Project of Qinghai Provincial Science and Technology Department (grant No. 2017-ZJ-907).

ORCID iD
Yujuan Qi https://orcid.org/0000-0002-0098-6813

References
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
2. Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018; 10: 239–248.
3. Hu Y, Fang JY and Xiao SD. Can the incidence of gastric cancer be reduced in the new century? J Dig Dis 2013; 14: 11–15.
4. Ying HY, Yu BW, Yang Z, et al. Interleukin-1B 31 C>T polymorphism combined with Helicobacter pylori-modified gastric cancer susceptibility: evidence from 37 studies. J Cell Mol Med 2016; 20: 526–536.
5. Yusefi AR, Lankarani KB, Bastani P, et al. Risk factors for gastric cancer: a systematic review. Asian Pac J Cancer Prev 2018; 19: 591–603.
6. Teresa F, Serra N, Capra G, et al. Helicobacter pylori and Epstein–Barr virus infection in gastric diseases: correlation with IL-10 and IL1RN polymorphism. J Oncol 2019; 2019: 1785132.
7. Morales-Sanchez A and Fuentes-Panana EM. Epstein-Barr virus-associated gastric cancer and potential mechanisms of oncogenesis. Curr Cancer Drug Targets 2017; 17: 534–554.
8. Nobili S, Bruno L, Landini I, et al. Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol 2011; 17: 290–299.
9. Hudler P. Genetic aspects of gastric cancer instability. ScientificWorldJournal 2012; 2012: 761909.
10. Saito M, Okayama H, Saito K, et al. CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancer. Oncol Lett 2017; 14: 6184–6190.
11. Ayazi G, Pirayesh M and Yari K. Analysis of interleukin-1β gene polymorphism and its association with generalized aggressive periodontitis disease. DNA Cell Biol 2013; 32: 409–413.
12. Taniguchi K and Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014; 26: 54–74.
13. Ismaili A, Yari K, Moradi MT, et al. IL-1B (C+3954T) gene polymorphism and susceptibility to gastric cancer in the Iranian population. Asian Pac J Cancer Prev 2015; 16: 841–844.
14. Li L, Tang XY, Ye LM, et al. Investigation on the association between IL-10 C819T gene polymorphisms and susceptibility to gastric cancer. Genet Mol Res 2016; 15: gmr15047915.
15. Jiang J, Zhao JH, Wang XL, et al. Analysis of mitochondrial DNA in Tibetan gastric cancer patients at high altitude. Mol Clin Oncol 2015; 3: 875–879.
16. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–132.
17. Sepulveda AR. Helicobacter, inflammation, and gastric cancer. Curr Pathobiol Rep 2013; 1: 9–18.
18. Lee DY, Hong SW, Chang YG, et al. Clinical significance of preoperative inflammatory parameters in gastric cancer patients. J Gastric Cancer 2013; 13: 111–116.
19. Wessler S, Krisch LM, Elmer DP, et al. From inflammation to gastric cancer—the importance of Hedgehog/GLI signaling in Helicobacter pylori-induced chronic
inflammatory and neoplastic diseases. Cell Commun Signal 2017; 15: 15.
20. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095–2147.
21. Wallace JL, Cucala M, Mugridge K, et al. Secretagogue-specific effects of interleukin-1 on gastric acid secretion. Am J Physiol 1991; 261: 559–564.
22. Nicklin MJ, Weith A and Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 1994; 19: 382–384.
23. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 204: 398–402.
24. Wen YY, Pan XF, Loh M, et al. Association of the IL-1B +3954 C/T polymorphism with the risk of gastric cancer in a population in Western China. Eur J Cancer Prev 2014; 23: 35–42.
25. Wang YM, Li ZX, Tang FB, et al. Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population. Tumour Biol 2016; 37: 2233–2242.
26. Palena C, Hamilton DH and Fernando RI. Influence of IL-8 on the epithelial–mesenchymal transition and the tumor microenvironment. Future Oncol 2012; 8: 713–722.
27. Ahuja SK, Ozcelik T, Milatovitch A, et al. Molecular evolution of the human interleukin-8 receptor gene cluster. Nat Genet 1992; 2: 31–36.
28. Mukaida N, Shiroo M and Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol 1989; 143: 1366–1371.
29. Wu CC, Huang YK, Chung CJ, et al. Polymorphism of inflammatory genes and arsenic methylation capacity are associated with urothelial carcinoma. Toxicol Appl Pharmacol 2013; 272: 30–36.
30. Chang YW, Oh CH, Kim JW, et al. Combination of Helicobacter pylori infection and the interleukin 8-251T>A polymorphism, but not the mannose-binding lectin 2 codon 54G>A polymorphism, might be a risk factor of gastric cancer. BMC Cancer 2017; 17: 388.
31. Xue H, Liu J, Lin B, et al. A meta-analysis of interleukin-8 -251 promoter polymorphism associated with gastric cancer risk. PLoS One 2012; 7: e28083.
32. Rojas JM, Avia M, Martin V, et al. IL-10: a multifunctional cytokine in viral infections. J Immunol Res 2017; 2017: 6104054.
33. Oft M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res 2014; 2: 194–199.
34. Eskdale J, Kube D, Tesch H, et al. Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics 1997; 46: 120–128.
35. Trifunović J, Miller L, Debeljak Ž, et al. Pathologic patterns of interleukin 10 expression—a review. Biochem Med (Zagreb) 2015; 25: 36–48.
36. Wang P, An J, Zhu Y, et al. Association of three promoter polymorphisms in interleukin-10 gene with cancer susceptibility in the Chinese population: a meta-analysis. Oncotarget 2017; 8: 62382–62399.
37. Yu T, Lu Q, Ou XL, et al. Clinical study on gastric cancer susceptibility genes IL-10-1082 and TNF-α. Genet Mol Res 2014; 13: 10909–10912.
38. Namazi A, Forat-Yazdi M, Jafari M, et al. Association of interleukin-10-1082 A/G (rs1800896) polymorphism with susceptibility to gastric cancer: meta-analysis of 6,101 cases and 8,557 controls. Arq Gastroenterol 2018; 55: 33–40.
39. Matalliotakis M, Zervou MI, Eliopoulos E, et al. The role of IL-16 gene polymorphisms in endometriosis. Int J Mol Med 2018; 41: 1469–1476.
40. Tang YJ, Wang JL, Xie KG, et al. Association of interleukin 16 gene polymorphisms and plasma IL16 level with osteosarcoma risk. Sci Rep 2016; 6: 34607.
41. Kim HS. Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping. Cytogenet Cell Genet 1999; 84: 93.
42. Glas J, Török HP, Unterhuber H, et al. The -295T-to-C promoter polymorphism of the IL-16 gene is associated with Crohn’s disease. Clin Immunol 2003; 106: 197–200.
43. Zhang T and Wang H. Variants of interleukin-16 associated with gastric cancer risk. Asian Pac J Cancer Prev 2013; 14: 5269–5273.

44. Xu LL, Song ZC, Shang K, et al. Non-association of IL-16 rs4778889 T/C polymorphism with cancer risk in Asians: a meta-analysis. Asian Pac J Cancer Prev 2014; 15: 803–805.

45. Lee JH, Cho DH and Park HJ. IL-18 and cutaneous inflammatory diseases. Int J Mol Sci 2015; 16: 29357–29369.

46. Vidal-Vanaclocha F, Mendoza L, Telleria N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006; 25: 417–434.

47. Born TL, Thomassen E, Bird TA, et al. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem 1998; 273: 29445–29450.

48. Tsutsumi N, Kimura T, Arita K, et al. The structural basis for receptor recognition of human interleukin-18. Nat Commun 2014; 5: 5340.

49. Babar M, Ryan AW, Anderson LA, et al. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma. Am J Gastroenterol 2012; 107: 1331–1341.

50. Zhu J, Liu C, Teng X, et al. Association of the interleukin-18 receptor 1 and interleukin-18 receptor accessory protein polymorphisms with the risk of esophageal cancer. Biomed Rep 2016; 4: 227–235.

51. Dudakov JA, Hanash AM and Van Den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol 2015; 33: 747–785.

52. Hu J, Li Y, Chen L, et al. Impact of IL-22 gene polymorphism on human immunodeficiency virus infection in Han Chinese patients. J Microbiol Immunol Infect 2016; 49: 872–878.

53. Lim C and Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev 2014; 25: 257–271.

54. Zhang J, Zhao T, Xu C, et al. Four polymorphisms in the IL-22 gene and the risk of cancer: a meta-analysis. J Evid Based Med 2018; 11: 101–104.

55. Qin SY, Yang XW, Luo W, et al. Association of interleukin 22 polymorphisms with gastric cancer risk. Tumour Biol 2015; 36: 2033–2039.

56. Damen MSMA, Popa CD, Netea MG, et al. Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases. Atherosclerosis 2017; 264: 83–91.

57. Kim SH, Han SY, Azam T, et al. Interleukin-32: a cytokine and inducer of TNFα. Immunity 2005; 22: 131–142.

58. Oh JH, Cho MC, Kim JH, et al. IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene 2011; 30: 3345–3359.

59. Tsai CY, Wang CS, Tsai MM, et al. Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin Cancer Res 2014; 20: 2276–2288.

60. Yun HM, Oh JH, Shim JH, et al. Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals. Cell Death Dis 2013; 4: e640.

61. Zeng Q, Li S, Zhou Y, et al. Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine 2014; 65: 24–32.

62. Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell 2009; 15: 283–293.

63. Park ES, Yoo JM, Yoo HS, et al. IL-32γ enhances TNF-α-induced cell death in colon cancer. Mol Carcinog 2014; 53: E23–E35.

64. Hong JT, Son DJ, Lee CK, et al. Interleukin 32, inflammation and cancer. Pharmacol Ther 2017; 174: 127–137.

65. Błogowski W, Madej-Michniewicz A, Marczuk N, et al. Interleukins 17 and 23 in patients with gastric neoplasms. Sci Rep 2016; 6: 37451.

66. Madej-Michniewicz A, Budkowska M, Salata D, et al. Evaluation of selected interleukins in patients with different gastric neoplasms: a preliminary report. Sci Rep 2015; 5: 14382.